At a glance
ClinicalIndex Comparison RecordPhase 4Completed· 148 enrolled
Drug / intervention
fixed combination of brimonidine tartrate 0.2% timolol maleate 0.5% ophthalmic solution +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
An Evaluation of the Fixed Combination Brimonidine Tartrate 0.2%/ Timolol Maleate 0.5% to Latanoprost 0.005% in Glaucoma or Ocular Hypertension Subjects
In Brief
A Phase 4 clinical trial evaluating fixed combination of brimonidine tartrate 0.2% timolol maleate 0.5% ophthalmic solution and latanoprost 0.005% for Glaucoma and Ocular Hypertension. Completed, enrolled 148 participants across 1 site.
Detailed Summary
A three-month evaluation comparing the safety and efficacy of a fixed combination of 0.2% brimonidine tartrate/0.5% timolol maleate with that of latanoprost 0.005%, a prostaglandin analogue in glaucoma or ocular hypertension subjects
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsGlaucoma, Ocular Hypertension
CountriesUnited States
Collaborators--
Timeline
Phase 4CompletedFinished
200920102011201220132014201520162017201820192020202120222023202420252026
Enrollment StartDec 2008
First PostedDec 2008
Primary CompletionJan 2010
TodayJul 2026
First PostedDec 19, 2008
Enrollment StartDec 1, 2008
Primary CompletionJan 1, 2010
TodayJul 2, 2026
Enrollment to primary: 1.1 yearsPosted 17.5 years ago
Interventions
fixed combination of brimonidine tartrate 0.2% timolol maleate 0.5% ophthalmic solutiondrug
1 drop of study medication taken approximately 12 hours apart, dosed 2 times a day
latanoprost 0.005%drug
1 drop of study medication taken once daily